By Fineline Cube 
Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing Gulou Hospital. The hospital will hand over proprietary knowledge of its NK‑cell–specific antigen CD16a and its tumor‑specific antigen cell‑adaptor platform to Jinling. The company will assume responsibility for subsequent development, manufacturing, and commercialization of the technology. The total value of the transaction is RMB 78.5 million.
Transaction Highlights
| Item | Details |
|---|---|
| Parties | Jinling Pharmaceutical & Nanjing Gulou Hospital |
| Technology | CD16a‑targeted NK‑cell cell adaptor, enabling antigen‑specific tumor killing without transfection |
| Contract Value | RMB 78.5 million (full payment) |
| Scope | Jinling to lead research, scale‑up, and market the platform |
Strategic Significance
- NK‑Cell Efficacy – The CD16a adaptor attaches directly to the anchoring protein on NK‑cell surfaces, amplifying their anti‑tumor response.
- Speed to Market – The technology transfer eliminates the need for extensive in‑house R&D, shortening the time from bench to clinic.
- Portfolio Expansion – The deal positions Jinling to broaden its oncology pipeline with a next‑generation immunotherapy platform.
Forward‑Looking Statements
This release contains forward‑looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed.-Fineline Info & Tech